Drug companion protocol

Saxenda

Prescription only

GLP-1 receptor agonist

Active ingredient: Liraglutide

A GLP-1 receptor agonist prescribed for chronic weight management in adults and adolescents.

Quickstart Highlights

Drug class: GLP-1 receptor agonist
Route: Subcutaneous injection
Schedule: Daily subcutaneous injection
Evidence score: 82

Quickstart highlights

💉Subcutaneous injection
🔬GLP-1 receptor agonist
🖊️Pre-filled autoinjector pen
📋Prescription required

General information only — not medical advice.Always follow your prescriber's instructions.

How this works

Mechanism of action and pharmacokinetic profile from published data.

Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a daily-injected analogue of the gut hormone GLP-1. It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. In Saxenda, the dose is 3.0 mg once daily (higher than the 1.2–1.8 mg daily doses used in Victoza for type 2 diabetes). Saxenda is one of the earliest approved GLP-1 agonists for weight management and has the most extensive real-world safety data of this medicine class.

Half-life

13 h

Tmax

10 h

Duration of action

24 h

Time to peak (Tmax): 8–12 hours after a subcutaneous injection.
Clearance: Degraded via proteolytic pathways; no renal or hepatic dose adjustment required for mild-to-moderate impairment, though limited data exist for severe impairment.
Elimination half-life: Approximately 13 hours — this is why Saxenda is injected once daily, unlike the once-weekly GLP-1 agonists.
Bioavailability: ~55% bioavailability after subcutaneous injection; ~98% albumin-bound.

Injection guide

Supplies, step-by-step technique, safety notes, and AU sharps disposal.

Dose escalation phases

Standard Saxenda escalation

Phase	Dose	Frequency	Guidance
Week 1 Week 1-1	0.6 mg	once daily	Initiation dose for tolerability. Do not start at the target dose.
Week 2 Week 2-2	1.2 mg	once daily	First escalation step. Delay escalation if not tolerated, under prescriber guidance.
Week 3 Week 3-3	1.8 mg	once daily	Intermediate escalation step. Assess GI tolerability before increasing.
Week 4 Week 4-4	2.4 mg	once daily	Pre-maintenance step. Hold if side effects limit escalation.
Week 5 onward Week 5+	3 mg	once daily	Target maintenance dose. Review response after 12 weeks on 3 mg.

Supplies needed

◦Your Saxenda pen — Each pen contains 18 mg/3 mL of liraglutide (6 mg/mL). One pen provides multiple daily injections — it will last varying numbers of days depending on your current dose in the escalation schedule.
◦A new pen needle (each day) — NovoFine or equivalent, 4 mm × 32G recommended. A fresh needle is required for every daily injection.
◦Alcohol swab
◦Sharps disposal container

Step-by-step

1Wash your hands
2Check the pen
The liquid should be clear and colourless. Check the remaining doses counter to confirm there is enough for your dose today. Check the expiry date.
3Attach a new needle
Remove the outer cap paper tab, push and twist the needle onto the pen, remove the outer cap (save it), then pull off and discard the inner needle cap.
4Dial your current dose
Turn the dose selector to your current prescribed dose: 0.6, 1.2, 1.8, 2.4, or 3.0 mg. Your dose increases weekly during the escalation period — confirm your current week's target with your prescriber.
5Prime if this is a new pen
If this is a new pen, dial 0.6 mg, point the pen upward, and press the button until a drop appears. Repeat until a drop is seen.
6Choose and clean your injection site
Abdomen (not within 5 cm of the navel), upper thigh, or upper arm. Rotate the site daily — not the same spot twice in a row. Clean with an alcohol swab.
7Inject
Hold the pen at 90° to the skin, press firmly and press the injection button all the way. Count slowly to 6 — hold until the dose counter reads 0.
8Remove needle and dispose
Recap with the saved outer cap (one-hand scoop), unscrew, and drop into your sharps container.
9Return pen to fridge
Store between 2–8°C. After first use the pen can be kept at room temperature (below 30°C) for up to 30 days.

Important notes

!Never inject into a vein or muscle
!Never share your pen
!Rotate injection sites daily
With daily injections, rotation is especially important — using the same spot causes lipohypertrophy (hardened fatty lumps) that impairs absorption.
!Do not inject into scar tissue, bruises, or broken skin
!A 4% weight-loss check applies at 16 weeks on 3.0 mg
If less than 4% of body weight has been lost by week 16 at the full dose, your prescriber will review whether to continue.
!Tell all healthcare providers you are using Saxenda

Sharps disposal

◦Sharps container — do not place loose needles in household bins
◦NestSafe mail-back (Australia) — free from participating pharmacies
◦EnviroSafe mail-back (Australia)
◦Community pharmacy drop-off — ask your dispensing pharmacy

Your journey

Where you are in a typical protocol, and what one dose cycle looks like. Educational — your prescriber tailors the plan to you.

Protocol timeline

Ongoing maintenance
Weeks 6+
3 mg
every 1d
What to expect: Sustained appetite regulation and weight management, GI side effects typically resolve or significantly diminish, Weight loss trajectory varies by individual — typically gradual, Ongoing benefit is dependent on continued use alongside diet and activity
Focus on: Maintaining consistent daily injection routine, Regular prescriber appointments for monitoring, Sustainable nutrition and physical activity habits, Monitoring for any new or recurring side effects
Common adjustments: Prescriber will assess response at 16 weeks — guidelines suggest reviewing if less than 4% weight loss has occurred, Dose remains at 3.0 mg unless tolerability requires adjustment
Starter phase
Weeks 1–1
0.6 mg
every 7d
What to expect: Body begins adjusting to liraglutide, Mild appetite reduction may begin, Nausea and gastrointestinal discomfort are most common in this early period, Injection-site reactions (redness, itching) may occur
Focus on: Establishing a consistent daily injection time, Learning correct injection and storage technique, Tracking nausea and appetite patterns, Staying well hydrated
Common adjustments: Injection technique review with prescriber or nurse, Rotating injection sites (abdomen, thigh, upper arm) to reduce site reactions, Small, frequent meals to manage nausea
First dose increase
Weeks 2–2
1.2 mg
every 7d
What to expect: Increased appetite suppression, Nausea may increase temporarily after each dose step-up, Gastric emptying slowing may become more noticeable
Focus on: Monitoring nausea severity and reporting if score is consistently above 5/10, Observing bowel habit changes — constipation may begin, Continuing hydration goals
Common adjustments: Eating smaller portions and avoiding high-fat meals around dosing, Prescriber may delay escalation if tolerability is poor
Second dose increase
Weeks 3–3
1.8 mg
every 7d
What to expect: Continued appetite suppression, GI side effects (nausea, constipation) may peak during this step, Some people notice early weight changes
Focus on: Tracking weekly weight, Reporting persistent vomiting or inability to tolerate fluids promptly, Building sustainable eating habits rather than restriction
Common adjustments: Prescriber may pause escalation for one to two weeks if nausea is unmanageable, Dietary fibre and fluid increases to support bowel regularity
Third dose increase
Weeks 4–4
2.4 mg
every 7d
What to expect: Approaching near-therapeutic dose — appetite effects strengthen, GI tolerance often improves as the body adapts, Energy levels may fluctuate
Focus on: Ensuring adequate protein and nutrient intake despite reduced appetite, Noting any mood changes and discussing with prescriber, Monitoring bowel frequency
Common adjustments: Prescriber may hold dose if side effects remain significant, Review of caloric adequacy if appetite is significantly reduced
Target maintenance dose reached
Weeks 5–5
3 mg
every 7d
What to expect: Full therapeutic dose of 3.0 mg/day achieved, Appetite suppression and satiety effects at maximum, GI symptoms typically begin to settle after 4–8 weeks at maintenance, Meaningful weight changes become more apparent
Focus on: Committing to long-term lifestyle changes alongside medication, Regular check-ins with prescriber (typically 4–12 weekly), Tracking weight, energy and wellbeing trends over time
Common adjustments: Prescriber review of weight trajectory and tolerability, If 3.0 mg is not tolerated, prescriber may discuss alternative plans

One dose cycle at a glance

Population typicals, in hours from your dose — individual experience varies.

Onset

1 h

Peak effect

8–12 h

Appetite effect

4–24 h

Nausea risk

2–14 h

Constipation risk

0–168 h

Coverage fades after

24 h

Liraglutide has a half-life of approximately 13 hours and reaches peak plasma concentration (tmax) at 8–12 hours after subcutaneous injection. Appetite suppression spans most of the 24-hour dosing interval, supporting once-daily dosing. Nausea risk is highest during the tmax window (roughly 2–14 hours post-dose). Constipation is a cumulative effect of slowed gastric emptying and tends to persist across the full dosing cycle rather than tracking a discrete window. Coverage fades after approximately 24 hours, hence strict daily dosing is important. Bioavailability is approximately 55% via subcutaneous route; ~98% albumin-bound. Degraded via proteolytic pathways — no renal or hepatic dose adjustment required for mild-to-moderate impairment.

Clinical Benefits & Side Effects

Observed outcomes, adverse effects, and lifecycle considerations from published trial data.

Benefits

Week 0

Starting at 0.6 mg daily

Saxenda is injected once daily, beginning at 0.6 mg for the first week. This is a tolerability dose — weight loss begins at 1.2 mg and above. Daily injection is a habit that takes a few days to settle into.

Week 1

First injection — taking the first step

This week is all about getting comfortable with your daily injection routine. You may feel mild nausea, especially after meals — this is very common and a sign the medication is working in your body. Don't expect visible weight changes yet; your body is simply adjusting to a new medication.

Week 2

Building the habit, riding the waves

Nausea may still be present, particularly in the mornings or after eating too quickly or too much. Try eating smaller portions and slowing down at meals to ease discomfort. You're still on a low starting dose — be patient with yourself and focus on consistency over results.

Week 3

Side effects may ease — routine takes shape

Many people find nausea begins to settle a little by week three as the body adapts. You might also notice some mild fatigue or occasional headaches — staying well hydrated can help with both. Keep showing up for your daily injection, even when it feels like not much is happening yet.

Week 4

End of starting dose — almost at escalation

You've completed your first month — that's worth acknowledging. Some people notice a subtle reduction in hunger or slightly smaller portions feeling satisfying, but many don't yet — both are completely normal. Your prescriber will likely guide a dose increase soon; follow your prescriber's instructions for the escalation schedule.

Week 4

Reaching 1.8 mg and assessing early tolerability

The dose steps up weekly (0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg). By week 4 most people are on 1.8 mg. GI side effects — if they occur — typically appear in the first 4 weeks and ease with time.

Week 5

Dose escalation begins — appetite shifts ahead

Your dose is stepping up this week, which may bring a temporary return of nausea or a new wave of side effects as your body adjusts to the higher level. This is expected and usually settles within a few days — stick with small, simple meals and keep up your fluids. Appetite suppression often becomes more noticeable as the dose increases.

Week 5

Target dose of 3.0 mg

The target dose is 3.0 mg daily. Your prescriber may hold you at a lower dose if it is effective and well tolerated. Most of the SCALE trial weight-loss data was generated at 3.0 mg.

Side effects

◦Constipation(mild)

~19%

Increase fluids, fibre-rich foods, and gentle movement; consider pharmacist advice for a short-term stool softener if needed.Seek help: Contact a clinician for severe abdominal pain, no bowel movement for several days, or vomiting with constipation.

◦Nausea(mild-to-moderate)

~32%; most common during dose escalation

Eat smaller, slower meals; choose bland lower-fat foods during escalation; avoid lying down soon after eating.Seek help: Contact your prescriber if nausea is severe, persistent, or prevents eating and drinking.

◦Dyspepsia(mild)

Reported

◦Headache(mild)

Common; often in early weeks

◦Vomiting(mild-to-moderate)

~16%

Pause solid food briefly, sip fluids, and restart bland foods once settled; do not escalate dose while vomiting persists.Seek help: Seek urgent advice for repeated vomiting, dehydration, or inability to keep fluids down.

◦Injection-site reaction(mild)

Mild; generally transient

Rotate sites, let alcohol dry before injecting, and avoid bruised, scarred, or hardened skin.Seek help: Seek advice for spreading redness, warmth, pus, fever, or severe pain.

◦Decreased appetite(mild)

Very common; generally an intended effect

◦Diarrhoea(mild)

~21%

Prioritise fluids and electrolytes; avoid alcohol, greasy meals, and very high-sugar drinks until symptoms settle.Seek help: Seek help if diarrhoea is severe, bloody, accompanied by fever, or causes dehydration.

Lifecycle factors

A 4% weight-loss check applies at 16 weeks

If less than 4% of body weight has been lost by week 16 at 3 mg, current clinical guidelines suggest reviewing whether Saxenda is working for you. This is not a failure — it means your prescriber will reassess.

Tell all medical teams about the daily injection

Delayed gastric emptying matters for surgical procedures. Also worth noting for any prescriber considering new oral medicines.

Track your progress in a simple journal or app

Keeping a brief weekly log — noting your weight, energy, how meals felt, any side effects, and one non-scale win — creates a valuable picture of your journey over time. It's also very motivating to look back at week two when you're at week ten and see how far you've come. A simple notes app on your phone, a dedicated app like MyFitnessPal, or even a paper notebook all work equally well.

Be open with your prescriber about side effects

Nausea, constipation, reflux, and fatigue are all common experiences on liraglutide — and your prescriber wants to know about them. If side effects are significantly affecting your quality of life or your ability to eat and drink adequately, don't wait until your next scheduled appointment to mention it. Your prescriber may have practical strategies to help, or may adjust the pace of your dose escalation — always follow your prescriber's instructions rather than making changes on your own.

Dispose of used needles safely using a sharps container

Used pen needles must never be placed in regular household bins — they should be collected in an approved sharps disposal container. In Australia, you can obtain a free sharps container through the Sharps Disposal Program available at many community pharmacies, councils, and healthcare centres. Once full, return the sealed container to a participating pharmacy or collection point for safe disposal.

Important note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All information presented is based on published clinical trial data. Always follow your prescriber's instructions.

Nutrition & practical guidance

Food, hydration, and adherence tips compiled from trial data and clinical companion content.

Food and hydration

✅ Prefer

Lean protein (chicken, fish, eggs, tofu, legumes)Non-starchy vegetables (leafy greens, zucchini, broccoli, cucumber)Lean protein at every mealNon-starchy vegetablesPlain crackers, rice, or toast (when nauseous)Low-fat yoghurt and cottage cheeseFibre-rich whole grains and legumesOats and wholegrains (e.g., rolled oats, brown rice, wholemeal bread)Small, regular meals

⚠️ Limit

High-fat takeaway and fast food (e.g., hot chips, fried chicken, burgers)Fried and very fatty foodsSugary drinks and fruit juices

Adherence tips

administration

Rotate your injection sites consistently

Liraglutide is injected subcutaneously (under the skin) into the abdomen, upper thigh, or upper arm — rotating between these sites each day helps prevent skin irritation and lumps from building up. Keep a simple mental or written log of where you injected last. Always follow your prescriber's instructions on injection technique, and if you're unsure, ask your pharmacist for a demonstration.

administration

Let the pen reach room temperature before injecting

Injecting liraglutide straight from the fridge can increase stinging and discomfort at the injection site. Take your pen out 10–15 minutes before your scheduled injection time to let it reach room temperature. Store unused pens in the fridge (2–8°C), and once opened, the current pen can be kept at room temperature (below 30°C) for up to 30 days.

administration

Daily injections become routine quickly

Most people find the first week of daily injections the hardest psychologically. Using the same time each day (e.g. with breakfast, or before bed) anchors it to an existing habit. The pen is designed to be simple — once the technique is set, the injection itself takes under a minute.

timing

Inject at the same time every day

Liraglutide is a once-daily injection and works best when taken at a consistent time each day — morning tends to suit most people as it becomes part of a morning routine. Linking your injection to an existing habit (like making your morning coffee or brushing your teeth) makes it much easier to remember. Always follow your prescriber's instructions if they've recommended a specific time for you.

nutrition

Prioritise protein at every meal

When your appetite is suppressed, it's easy to under-eat — and when you do eat less, protein is the most important nutrient to prioritise to protect your muscle mass. Aim for a palm-sized portion of protein (chicken, fish, eggs, legumes, Greek yoghurt) at breakfast, lunch, and dinner. Even on days when you're not very hungry, a small high-protein meal is far better than skipping entirely.

nutrition

The real-world dose matters for weight loss

All significant SCALE trial weight-loss data is at 3.0 mg daily. If you are held at 1.8 mg or 2.4 mg due to tolerability, it is worth an honest conversation with your prescriber about expected outcomes versus a weekly agent.

nutrition

Eat smaller meals more frequently

Large meals are one of the most common triggers for nausea on liraglutide — your stomach empties more slowly on this medication, so overshooting your new fullness threshold can feel very uncomfortable. Try eating 4–5 smaller meals or snacks spread throughout the day rather than three large ones. Stopping at the first sign of fullness, rather than finishing your plate, is a habit worth building early.

mindset

Saxenda is a foundation, not a ceiling

If you respond well to Saxenda but your prescriber later discusses switching to a weekly agent, this is a clinical upgrade, not a sign of failure. The GLP-1 medicine class has evolved significantly since liraglutide was first approved.

hydration

Sip water steadily — don't gulp large amounts at once

Drinking large volumes of water quickly can worsen bloating and nausea, especially around meal times. Instead, keep a 600 mL or 1 litre water bottle with you and sip steadily throughout the day, aiming for at least 2 litres total. Try not to drink large amounts of fluid during meals, as this can increase feelings of fullness and discomfort.

hydration

Try ginger or peppermint tea for nausea

Ginger tea is one of the most well-supported natural remedies for nausea and is safe for most people to use alongside their medication. Keep herbal tea bags on hand — especially in the first four to six weeks — and sip on a warm cup when nausea strikes. Peppermint tea is another great option if ginger isn't to your taste.

mindset

Progress is not just the number on the scales

Weight loss with liraglutide is typically gradual and won't follow a perfectly straight line — some weeks the scales won't move even when you're doing everything right. Make a habit of tracking non-scale victories: improved sleep, more energy, smaller portions feeling satisfying, or feeling more comfortable in movement. These changes are meaningful and reflect real progress, even when the scales disagree.

mindset

The early weeks are the hardest — keep going

Weeks one through four can genuinely be tough — nausea, fatigue, and no visible results yet can make it hard to stay motivated. It's completely normal to wonder whether it's worth it during this phase. Most people find that side effects ease significantly after the adjustment period, and the benefits of the medication become much more apparent from around week five onwards. You're building the foundation right now.

exercise

Start with gentle movement — not an intense gym programme

In the early weeks when nausea and fatigue are common, gentle movement is far more sustainable than jumping straight into a demanding exercise routine. A 20–30 minute walk each day is an excellent starting point and pairs well with the medication's effects. As you feel better and your energy improves — typically from around week six — you can gradually build in strength training, which is particularly valuable for preserving muscle during weight loss.

exercise

Time exercise around your best-feeling window

If nausea is worse in the mornings after your injection, scheduling your walk or workout for the afternoon or evening when you're feeling better makes exercise far more enjoyable and sustainable. Listen to your body — there's no single "right" time to exercise, and consistency matters far more than timing. Aim for at least 150 minutes of moderate movement per week as a long-term goal, in line with Australian physical activity guidelines.

sleep

Protect your sleep — it directly supports weight management

Poor sleep increases hunger hormones (particularly ghrelin) and can partially counteract the appetite-regulating benefits of liraglutide. Aim for 7–9 hours of quality sleep per night by keeping a consistent bedtime, limiting screen use in the hour before bed, and keeping your bedroom cool and dark. If disrupted sleep is an ongoing issue, it's worth raising with your prescriber as part of your broader health picture.

Daily companion

Practical playbooks for managing symptoms, eating around side effects, tracking what matters, and reporting back to your clinician.

Symptom playbooks

Nausea

Minimal or no nausea

score 0–2

Nutrition: Continue eating regular balanced meals, Focus on protein-rich foods at each meal to support satiety, Eat slowly and mindfully — liraglutide slows gastric emptying so meals are processed more slowly

Hydration: Aim for approximately 2 litres of fluid per day, Sip water steadily throughout the day rather than drinking large amounts at once

Avoid: Overeating — stomach emptying is slower than usual

Mild nausea

score 3–5

Nutrition: Eat small, frequent meals (4–6 per day) rather than large portions, Choose bland, low-fat foods such as plain crackers, rice, toast, or boiled chicken, Avoid eating large meals close to your injection time, Ginger-containing foods (ginger tea, ginger biscuits) may help some people, Eat slowly and stop before feeling full

Hydration: Sip cool or room-temperature water frequently, Cold or room-temperature clear fluids (water, diluted cordial, clear broths) are generally better tolerated than hot drinks, Avoid carbonated drinks if they worsen discomfort

Avoid: High-fat or fried foods, Spicy foods, Strong food odours where possible, Large meals, Alcohol

⚠ If mild nausea persists for more than five to seven days without improvement, mention it at your next prescriber check-in.

Moderate nausea

score 6–8

Nutrition: Focus on very small amounts of easy-to-digest foods — even a few crackers or a piece of dry toast, Do not force eating if nausea is severe; prioritise fluids, Try cold foods (e.g. yoghurt, chilled fruit) if hot food smells worsen nausea, Avoid lying flat immediately after eating — remain upright for at least 30 minutes

Hydration: Prioritise staying hydrated with small, frequent sips, If plain water is unappealing, try diluted electrolyte drinks or clear broth, Aim for at least 1.5 litres of fluids even if solid food is difficult

Avoid: Fatty, fried, or greasy foods, Dairy-heavy meals, Spicy or strongly flavoured foods, Alcohol, Caffeine in excess

⚠ Contact your prescriber if moderate nausea lasts more than 48 hours, or if you are unable to keep fluids down. Your prescriber may consider pausing dose escalation or adjusting your plan.

Severe nausea or vomiting

score 9–10

Nutrition: Do not force food — focus entirely on hydration, If any food is tolerated, stick to plain, bland items in very small amounts

Hydration: Sip small amounts of clear fluids every 10–15 minutes, Use oral rehydration solutions if vomiting has occurred, Seek medical attention if you cannot keep any fluids down for more than 4–6 hours

Avoid: All foods that worsen symptoms, Alcohol, Solid food until vomiting resolves

⚠ Contact your prescriber promptly or seek urgent medical care if vomiting is persistent, you cannot keep fluids down, or you have severe abdominal pain alongside nausea. Severe or persistent vomiting with upper abdominal pain may warrant assessment for pancreatitis.

Constipation

No or minimal constipation

score 0–2

Nutrition: Maintain a fibre-rich diet with vegetables, legumes, whole grains, and fruit, Aim for 25–30 g of dietary fibre per day

Hydration: Aim for at least 2 litres of fluid per day to support bowel motility, Start each day with a glass of water

Avoid: Excessive refined or low-fibre foods (white bread, pastries, processed snacks)

Mild constipation

score 3–5

Nutrition: Increase dietary fibre gradually — add vegetables, legumes, oat bran, and flaxseeds, Try warm prune juice or stewed prunes, which can have a natural laxative effect, Include fibre at every meal

Hydration: Increase fluid intake to at least 2–2.5 litres per day, Warm fluids (e.g. warm water with lemon, herbal teas) in the morning may help stimulate bowels

Avoid: Low-fibre, highly processed foods, Excessive dairy if it worsens symptoms

⚠ If mild constipation has not improved after five to seven days of increased fibre and fluids, discuss with your prescriber — a gentle over-the-counter option may be appropriate.

Moderate constipation

score 6–8

Nutrition: Prioritise high-fibre foods at every meal, Consider a psyllium husk supplement (discuss with prescriber or pharmacist first), Keep meals regular — skipping meals can further slow gut motility

Hydration: Aim for 2.5–3 litres of fluid per day, Warm water or herbal tea first thing in the morning

Avoid: Constipating foods such as excessive cheese, red meat, and highly refined carbohydrates, Dehydrating beverages such as excessive alcohol or caffeine

⚠ Contact your prescriber if moderate constipation persists beyond seven days or is accompanied by significant abdominal discomfort. Do not use laxatives without discussing with your prescriber or pharmacist first.

Severe constipation

score 9–10

Nutrition: Focus on hydration as a priority, Do not force high-fibre foods if abdominal pain is present

Hydration: Maximise fluid intake, Warm fluids may help

Avoid: Foods that worsen bloating or discomfort, Self-medicating with stimulant laxatives without prescriber guidance

⚠ Contact your prescriber promptly if you have not had a bowel movement in more than five days, or if constipation is accompanied by severe abdominal pain, bloating, or vomiting. Seek urgent care if these symptoms are severe or rapidly worsening.

Appetite

Very low appetite

score 0–2

Nutrition: Prioritise nutrient-dense foods in small amounts — even a small portion of protein, healthy fat, and vegetables is valuable, Try liquid nutrition such as smoothies, protein shakes, or soups if solid food is unappealing, Eat by the clock rather than by hunger — set regular meal times every 3–4 hours, Focus on protein to preserve muscle mass

Hydration: Use fluids that also provide nutrition — milk, fortified plant milks, bone broth, Avoid drinking large amounts of water immediately before meals as this may further reduce intake

Avoid: Going more than 5–6 hours without any nutritional intake, Relying entirely on appetite cues to determine when to eat

⚠ If your appetite is so low that you are consistently unable to meet basic nutritional needs, or if you are losing weight very rapidly, contact your prescriber. Inadequate nutrition can affect your health and the safety of continued treatment.

Reduced appetite

score 3–5

Nutrition: Eat smaller, more frequent meals — 4–5 times per day, Choose nutrient-dense options: eggs, lean protein, nuts, avocado, dairy, legumes, Make each eating occasion count — avoid empty-calorie foods, A registered dietitian can help you plan adequate intake on a reduced appetite

Hydration: Aim for 2 litres of fluid per day, Drink fluids between meals rather than with meals to preserve stomach space for food

Avoid: Skipping meals entirely even when not hungry, Filling up on low-nutrient snacks or drinks

Normal or near-normal appetite

score 6–10

Nutrition: Use the medication window to practise mindful eating habits — eat slowly, stop at comfortable fullness, Focus on a balanced diet: vegetables, protein, whole grains, and healthy fats, This is a good opportunity to work with a dietitian to build sustainable habits

Hydration: Aim for 2 litres of fluid per day

Avoid: Large, high-fat meals which may worsen GI symptoms

Food guidance by situation

Nausea

Prefer: Plain crackers or dry toast, Boiled or steamed chicken or fish, Plain rice or plain pasta, Bananas, Ginger tea or ginger biscuits, Cold or room-temperature foods, Small, frequent snacks rather than large meals

Limit: Dairy-heavy dishes, High-sugar foods, Caffeinated beverages

Avoid: Fried or greasy foods, Spicy foods, Alcohol, Strong-smelling foods, Large meal portions

Liraglutide slows gastric emptying; high-fat and spicy foods further delay gastric clearance and can worsen nausea, particularly during the tmax window (8–12 hours post-dose).

Constipation

Prefer: Vegetables (broccoli, spinach, carrots, peas), Legumes (lentils, chickpeas, kidney beans), Whole grains (oats, brown rice, wholegrain bread), Fruit with skin (apples, pears, kiwi fruit), Prunes or prune juice, Flaxseeds or chia seeds, Warm water or herbal teas

Limit: White bread, white rice, and refined cereals, Excessive dairy, Processed or packaged snack foods

Avoid: Foods extremely low in fibre as the sole dietary staple, Excessive alcohol (dehydrating)

Slowed gastric motility from GLP-1 receptor agonism increases constipation risk. Adequate fibre (25–30 g/day) and fluid intake support bowel regularity.

Low appetite

Prefer: Protein-rich foods: eggs, Greek yoghurt, cottage cheese, canned fish, lean meat, legumes, Calorie-dense but small-volume foods: nut butters, avocado, olive oil, cheese, Fortified smoothies or protein shakes, Soups with protein and vegetables, Soft, easy-to-eat foods if appetite is very low

Limit: Low-nutrient snacks that fill stomach space without providing protein or micronutrients

Avoid: Going extended periods (more than 5–6 hours) without any nutritional intake

With significantly reduced appetite, caloric and protein adequacy must be prioritised to avoid muscle loss and nutritional deficiency. Dense nutrition in small volumes is key.

Dose-escalation week

Prefer: Bland, easily digested foods, Small, frequent meals (4–6 per day), Cooked vegetables over raw, Plain protein sources, Ginger tea

Limit: High-fibre raw vegetables if GI upset is significant, Large meal portions

Avoid: High-fat meals, Spicy foods, Alcohol (may worsen nausea and GI irritation), Carbonated drinks if they worsen bloating

GI side effects are most pronounced during and immediately after each dose step-up. A bland, low-fat, small-portion approach reduces nausea and GI discomfort during these windows.

Post-dose nausea window

Prefer: Very small, bland snacks if hungry, Cool or room-temperature fluids, Ginger-based options, Plain crackers or dry toast

Limit: Any large meal during the 8–14 hour post-dose window when nausea risk is highest

Avoid: High-fat meals, Alcohol, Spicy or rich foods

Nausea risk peaks during the tmax window (approximately 8–12 hours post-injection) when plasma liraglutide concentrations are highest. Light, bland food choices reduce symptom load during this period.

Reflux

Prefer: Small, frequent meals, Low-acid foods: bananas, melons, oats, lean protein, Remaining upright for at least 30 minutes after eating

Limit: Tomato-based sauces, Citrus fruits and juices, Chocolate, Caffeine, Mint

Avoid: Fatty or fried foods, Alcohol, Eating within 2–3 hours of lying down or sleeping, Large meals

Slowed gastric emptying from liraglutide may increase reflux symptoms. Standard reflux dietary strategies are particularly relevant during treatment.

What to track

Suggested check-in cadence: daily.

How would you rate your nausea today? (0 = none, 10 = worst imaginable)

scale 0 10

How many times did you vomit in the last 24 hours? (episodes)

integer

How would you rate your appetite today? (0 = no appetite at all, 10 = normal appetite)

scale 0 10

How much has constipation bothered you today? (0 = not at all, 10 = very severely)

scale 0 10

Did you have a bowel movement today?

boolean

How would you rate your energy levels today? (0 = exhausted, 10 = excellent)

scale 0 10

Approximately how many litres of fluid have you drunk today? (L)

decimal

What is your weight today? (Weigh yourself at the same time each week, e.g. morning before breakfast) (kg)

decimal

Have you had any abdominal or stomach pain today? (0 = none, 10 = severe)

scale 0 10

Did you notice any redness, swelling, or discomfort at your injection site today?

boolean

How would you rate your overall mood today? (0 = very low, 10 = very good)

scale 0 10

Take this to your appointment

Medication context: GLP-1 receptor agonist (liraglutide 3.0 mg/day — Saxenda)

Key metrics: Weekly weight (kg) — trend over past 4, 8, and 16 weeks, Current dose level and weeks since dose escalation, Average daily nausea score (0–10 scale) over past 7 days, Average daily appetite score (0–10 scale) over past 7 days, Constipation severity score (0–10 scale) — peak and average, Average daily energy score (0–10 scale) over past 7 days, Average daily fluid intake (litres) over past 7 days, Abdominal pain score — peak score in past 7 days, Number of vomiting episodes in past 7 days, Mood score trend (0–10) — flag if consistently ≤3, Any injection-site reactions reported (Y/N), Any red-flag symptom alerts triggered in past 30 days

Relevant symptoms: Nausea (severity, duration, relationship to dose timing), Vomiting (frequency, ability to maintain hydration), Constipation (days since last bowel movement, severity), Upper abdominal pain (rule out pancreatitis, gallbladder disease), Neck swelling or hoarseness (thyroid monitoring), Injection-site reactions, Increased resting heart rate, Mood changes or low mood, Signs of hypoglycaemia (if on concurrent insulin or sulfonylurea), Reflux or regurgitation, Fatigue or low energy

Safety and interactions

Share this information with your prescriber for personalised care decisions.

Red-flag symptoms — seek urgent care

Severe or persistent abdominal pain (especially upper abdomen, radiating to back)
Emergency
Severe abdominal pain — particularly in the upper abdomen or pain that radiates to your back — can be a sign of pancreatitis, a serious condition that has been reported with GLP-1 receptor agonists. Stop eating and seek emergency medical care immediately. Do not wait to see if symptoms improve on their own.
Persistent vomiting with inability to keep fluids down for more than 4–6 hours
Urgent care
If you are vomiting repeatedly and cannot keep any fluids down for more than 4–6 hours, you are at risk of dehydration. Seek urgent medical care. Bring a list of your current medications.
Lump or swelling in the neck, difficulty swallowing, or hoarse voice
Urgent care
A lump or swelling in the neck, difficulty swallowing, or a persistent hoarse voice can be signs of thyroid changes. Contact your prescriber promptly or seek urgent medical attention. Liraglutide carries a warning regarding thyroid C-cell tumours in animal studies.
Symptoms of a serious allergic reaction (swelling of face, lips, tongue or throat; difficulty breathing; severe rash or hives)
Emergency
Signs of a serious allergic reaction include swelling of the face, lips, tongue, or throat, difficulty breathing, or a severe rash. Call 000 (Australia) immediately. This is a medical emergency.
Rapid heartbeat (tachycardia) or pounding heartbeat at rest
Contact prescriber
Some people experience an increased heart rate with liraglutide. If you notice a persistently fast or pounding heartbeat at rest, contact your prescriber. This does not usually require emergency care, but your prescriber should assess it.
Symptoms of low blood sugar (hypoglycaemia) if also taking insulin or a sulfonylurea: shakiness, sweating, confusion, or loss of consciousness
Urgent care
Liraglutide alone has a low risk of hypoglycaemia, but the risk increases if you are also taking insulin or a sulfonylurea. If you feel shaky, sweaty, confused, or faint, follow your prescriber's hypoglycaemia management plan. Seek urgent care if symptoms do not resolve or are severe.
Thoughts of self-harm or suicide, or significant worsening of mood
Urgent care
Rare reports of suicidal ideation have been noted across weight-management medicines. If you are having thoughts of harming yourself, please reach out immediately. In Australia, call Lifeline on 13 11 14 or go to your nearest emergency department. Also contact your prescriber as soon as possible.
Signs of gallbladder problems: sudden severe pain in the upper-right abdomen, nausea, vomiting, fever
Urgent care
Weight loss can increase the risk of gallstones. Sudden severe pain in the upper-right abdomen, especially with fever and nausea, may indicate a gallbladder problem. Seek urgent medical care.
Thyroid C-cell tumour warning. Do not use Saxenda with a personal or family history of medullary thyroid carcinoma or MEN2.
Pancreatitis symptoms. Stop and seek urgent assessment for severe persistent abdominal pain, especially with vomiting or pain radiating to the back.
Thyroid tumour risk. Liraglutide has caused thyroid tumours (including medullary thyroid carcinoma, MTC) in animal studies. Do not use Saxenda if you or a blood relative have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your prescriber straight away if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath.
Serious allergic reaction. Serious allergic reactions (anaphylaxis, angioedema) have been reported with liraglutide. Seek emergency help immediately if you develop swelling of your face, lips, tongue or throat, difficulty breathing, a rapid heartbeat, or feel faint after an injection.
Gallbladder problems. Saxenda increases the risk of gallstones and gallbladder inflammation (cholecystitis). Tell your prescriber straight away if you develop sudden, severe pain in the upper right side of your abdomen, fever, or yellowing of your skin or eyes.
Severe nausea, vomiting, or dehydration. Saxenda commonly causes nausea and vomiting, particularly early in treatment or after a dose increase. If you cannot keep fluids down, feel dizzy or faint, or are passing very little urine, contact your prescriber promptly — severe dehydration can affect your kidneys.

Structured warnings

Boxed warning

Thyroid C-cell tumour warning

Do not use Saxenda with a personal or family history of medullary thyroid carcinoma or MEN2.

Urgent

Pancreatitis symptoms

Stop and seek urgent assessment for severe persistent abdominal pain, especially with vomiting or pain radiating to the back.

Caution

Mood or suicidal thoughts

Report new or worsening depression, suicidal thoughts, or unusual mood changes promptly.

Boxed warning

Thyroid tumour risk

Liraglutide has caused thyroid tumours (including medullary thyroid carcinoma, MTC) in animal studies. Do not use Saxenda if you or a blood relative have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your prescriber straight away if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath.

Urgent

Serious allergic reaction

Serious allergic reactions (anaphylaxis, angioedema) have been reported with liraglutide. Seek emergency help immediately if you develop swelling of your face, lips, tongue or throat, difficulty breathing, a rapid heartbeat, or feel faint after an injection.

Urgent

Gallbladder problems

Saxenda increases the risk of gallstones and gallbladder inflammation (cholecystitis). Tell your prescriber straight away if you develop sudden, severe pain in the upper right side of your abdomen, fever, or yellowing of your skin or eyes.

Urgent

Severe nausea, vomiting, or dehydration

Saxenda commonly causes nausea and vomiting, particularly early in treatment or after a dose increase. If you cannot keep fluids down, feel dizzy or faint, or are passing very little urine, contact your prescriber promptly — severe dehydration can affect your kidneys.

Caution

Low blood sugar (hypoglycaemia)

The risk of low blood sugar is higher if you are also taking insulin or a sulfonylurea. Symptoms include shakiness, sweating, confusion, and a rapid heartbeat. Your prescriber may need to adjust your other diabetes medicines when starting Saxenda.

Caution

Dehydration from nausea, vomiting or diarrhoea

Nausea, vomiting, and diarrhoea — especially early in treatment — can lead to dehydration, which may affect kidney function. Stay well hydrated and contact your prescriber if you are unable to keep fluids down or symptoms are severe.

Caution

Mood changes and suicidal thoughts

Rare reports of depression and suicidal thoughts have been observed with weight-management medicines including liraglutide. Tell your prescriber promptly if you notice changes in your mood, thoughts of self-harm, or worsening mental health.

Indication and approval status

Approved

US · FDA

Chronic weight management as an adjunct to reduced-calorie diet and increased physical activity.

Adults and selected adolescents meeting label criteria.

Approved

AU · TGA

Weight management in adults meeting product-information eligibility criteria.

Adults according to Australian product information.

Who should not take this

Saxenda is a prescription medicine. Do not use if you have: • A personal or family history of medullary thyroid carcinoma (MTC) • Multiple endocrine neoplasia syndrome type 2 (MEN2) • A known allergy or hypersensitivity to liraglutide or any ingredient in the product Use with caution (discuss with your prescriber) if you have: • A history of pancreatitis • Severe kidney or liver disease • A history of suicidal ideation — rare reports have been observed across weight-loss medicines • Active or recent eating disorder Not recommended during pregnancy or breastfeeding. Saxenda is approved in AU for adults (18+) and in some regions for adolescents 12–17 years. Always discuss your full medical history with your prescriber.

Known interactions

Insulin and insulin secretagogues (e.g. sulfonylureas)
significant
Increased hypoglycaemia risk. Prescribers typically reduce doses of other glucose-lowering agents when starting Saxenda.
Oral contraceptives
moderate
Slowed gastric emptying may reduce oral contraceptive absorption, particularly during dose escalation. Consider additional non-hormonal contraception.
Narrow therapeutic index medicines (warfarin, anti-epileptics)
moderate
Altered absorption timing. Additional monitoring may be warranted.
Alcohol
moderate
Worsens nausea and dehydration; increases hypoglycaemia risk with other diabetes medicines.

Missed-dose guidance

If a daily Saxenda dose is missed, skip it and take the next dose the following day.

Do not take an extra dose or increase the next dose to make up for the missed dose.

If Saxenda has been missed for more than 3 days, contact the prescriber before restarting.

Restarting at a lower dose may be needed to reduce gastrointestinal side effects.

If you miss a dose, inject it as soon as you remember — provided your next scheduled dose is at least 12 hours away. If fewer than 12 hours remain until your next scheduled dose, omit the missed dose entirely and continue with your usual schedule the following day.

Do not inject two doses within 12 hours of each other. If you have missed several days of doses, contact your prescriber before restarting, as a dose-escalation review may be needed.

If you miss a dose, inject it as soon as you remember — provided your next scheduled dose is at least 8 hours away. If it is less than 8 hours until your next scheduled dose, omit the missed dose and continue with your usual daily schedule.

Do not inject two doses within 8 hours of each other. Resume your regular once-daily injection time the following day. If you miss more than 3 consecutive days, contact your prescriber before restarting, as a dose reduction and re-escalation may be required.

When to seek help

Nausea

Contact prescriber

Nausea that remains severe after dose escalation or prevents normal meals/fluids.

Contact your prescriber before increasing the dose.

Vomiting

Urgent care

Repeated vomiting, dehydration symptoms, or vomiting lasting more than 24 hours.

Seek medical advice promptly.

Mood changes

Urgent care

New or worsening depression, suicidal thoughts, or unusual mood changes.

Contact a clinician urgently; emergency help if there is immediate risk.

Side-effect timing windows

Population typicals from trial data — individual experience varies.

Nausea

Onset 1–12 h · Peak 6–24 h · Resolves ~28d

Daily dosing means each escalation step has its own settling period; full tolerance can take ~4 weeks.

Vomiting

Onset 2–12 h · Peak 6–24 h · Resolves ~14d

Diarrhoea

Onset 4–24 h · Peak 12–48 h · Resolves ~7d

Daily dosing means each escalation step has its own tolerance window.

Constipation

Onset 24–72 h · Peak 48–168 h · Resolves ~14d

Reported in approximately 19% of participants in the SCALE trial. Relates to slowed gastric emptying. Adequate fluid and fibre intake may help.

Injection-site reaction

Onset 0.5–4 h · Peak 1–24 h · Resolves ~3d

Includes localised redness, bruising, itching, or swelling at the injection site. Usually mild and short-lived. Regular site rotation reduces frequency and severity.

Headache

Onset 2–12 h · Peak 4–24 h · Resolves ~3d

Commonly reported particularly early in treatment. Usually mild and transient. Staying well hydrated may help.

Decreased appetite

Onset 1–8 h · Peak 4–12 h · Resolves —

A pharmacodynamic effect of GLP-1 receptor agonism at hypothalamic receptors. Appetite suppression is a treatment action but is listed here as some patients find early-stage appetite reduction pronounced and unexpected.

Approved injection sites

Abdomen

Preferred

Rotate daily between abdomen, thigh and upper arm. Move at least 2.5 cm from the prior site each day.

Avoid: Avoid skin that is bruised, tender, scarred or hardened.

Thigh

Front of the thigh.

Upper arm

Back of the upper arm.

Structured storage

multi-dose pen

before first use

Refrigerate at 2-8 C

Protect from light

Do not freeze

Keep capped and do not use if frozen, cloudy, or discoloured.

multi-dose pen

after first use

Below 30 C or refrigerated at 2-8 C

Protect from light

Do not freeze

Use within 30 days after first use.

Remove the needle after each injection and replace the pen cap.

Storage and handling

Store the Saxenda pen in the refrigerator at 2–8°C (36–46°F) until first use. • After first use: use within 30 days, keeping at or below 30°C and protected from light. • Do not freeze the pen — freezing destroys the medicine. • Keep the cap on when not in use. • The pen is for single patient use only — do not share.

Research evidence

Published studies, labels, regulator pages, and curated protocol sources connected to this profile.

API source references

prescribing information

US · FDA

Saxenda prescribing information

Novo Nordisk. Saxenda (liraglutide) prescribing information.

Open source ↗

regulator

AU · TGA

Saxenda product information

Therapeutic Goods Administration product information for Saxenda.

Open source ↗

study

Global · NEJM

SCALE obesity trial

Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015.

Open source ↗

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)

Human trial · 2016 · New England Journal of Medicine · n=9340 · Adults with type 2 diabetes and high cardiovascular risk

9,340 adults with type 2 diabetes and high cardiovascular risk were randomised to liraglutide 1.8 mg daily or placebo for a median of 3.8 years. MACE occurred in 13.0% of liraglutide versus 14.9% of placebo participants (HR 0.87, 95% CI 0.78–0.97), demonstrating cardiovascular safety and superiority.

Reported outcomes

cardiovascular: MACE occurred in 13.0% liraglutide versus 14.9% placebo over median 3.8 years (HR 0.87) — demonstrating CV safety and superiority in type 2 diabetes. (Primary outcome)

DOI: 10.1056/NEJMoa1603827 ↗

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity)

Human trial · 2015 · New England Journal of Medicine · n=3731 · Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with dyslipidaemia or hypertension, without type 2 diabetes

3,731 adults were randomised to liraglutide 3.0 mg once daily or placebo for 56 weeks, alongside diet and exercise counselling. Mean body-weight change was −8.4% with liraglutide versus −2.8% with placebo; 63.2% of liraglutide participants achieved ≥5% weight loss. Nausea and vomiting were the most common adverse events.

Reported outcomes

weight_loss: Mean body-weight reduction of 8.4% at 56 weeks on 3.0 mg daily, versus 2.8% with placebo. (Primary outcome)
cardiometabolic: Improvements in blood pressure, HbA1c, and lipids; 80% risk reduction in progression to type 2 diabetes in a prediabetes subgroup. (Secondary)
responder_rate: 63.2% of liraglutide participants achieved ≥5% weight loss; 33.1% achieved ≥10%. (Secondary)

Reported dosage

3 mg · once daily subcutaneous · 56 weeks — Reached after weekly escalation: 0.6→1.2→1.8→2.4→3.0 mg. Primary endpoint dose.

DOI: 10.1056/NEJMoa1411892 ↗

Get the full companion experience in Viora

Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.

Available on iOS and Android.

Top Dosing Benefits Evidence App signup